FDA places partial hold on Biohaven's epilepsy drug

The FDA has placed a partial clinical hold on Biohaven's epilepsy drug opakalim shortly after Biohaven sold the rights to the therapy, affecting a study considered important for potential approval.

This Wire brief sits within Fusion42's coverage of Biotech, and 3 sources have reported it.